Who
Colleen A. Goggins
Director
Company insider
Files Form 4 as: Director, IQVIA Holdings; Director, Bausch Health Companies; Member, Executive Committee, Johnson & Johnson.
In numbers
- Trades disclosed
- 152
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $8.5M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 30 Dec 2005
- Last trade
- 14 Jul 2026
- Last filed
- 16 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Jul 2026filed 16 Jul 2026 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $38K183 at $207.83 | filing |
| 14 Jul 2026filed 16 Jul 2026 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $38K183 at $207.83 | filing |
| 7 May 2026filed 11 May 2026 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $38K214 at $178.64 | filing |
| 7 May 2026filed 11 May 2026 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $38K214 at $178.64 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —1,571 at $0.00 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —1,571 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $38K198 at $192.67 | filing |
| 9 Feb 2026filed 11 Feb 2026 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $38K198 at $192.67 | filing |
| 5 Nov 2025filed 7 Nov 2025 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $38K181 at $210.12 | filing |
| 24 Jul 2025filed 28 Jul 2025 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K174 at $200.82 | filing |
| 7 May 2025filed 9 May 2025 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K229 at $153.30 | filing |
| 24 Apr 2025filed 25 Apr 2025 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —1,592 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K170 at $205.44 | filing |
| 6 Nov 2024filed 8 Nov 2024 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K158 at $221.25 | filing |
| 18 Jul 2024filed 22 Jul 2024 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K156 at $224.85 | filing |
| 7 May 2024filed 9 May 2024 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K153 at $229.14 | filing |
| 7 May 2024filed 9 May 2024 | IQV IQVIA HoldingsLife-science tools | SEC FORM 4 Code A | —1,047 at $0.00 | filing |
| 7 Feb 2024filed 9 May 2024 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K163 at $214.34 | filing |
| 9 Nov 2023filed 8 Feb 2024 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K182 at $191.91 | filing |
| 19 Jul 2023filed 8 Feb 2024 | IQV IQVIA Holdingsoption or derivative · Life-science tools | SEC FORM 4 Code A | $35K155 at $225.46 | filing |
News
Capital Group Core Balanced ETF (NYSE: CGBL) Opens New Position In Johnson & Johnson (NYSE: JNJ)JNJ · foreignpolicyjournal.com · 23 Oct 2026Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026JNJ · finanznachrichten.de · 22 Oct 2026Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?JNJ · aol.com · 21 Oct 2026
0 headlines in the last 90 days name Colleen A. Goggins; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.